Autologous Desmoglein-3 Chimeric Autoantibody Receptor T-cells DSG3-CAART

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes that have been engineered to express a chimeric autoantibody receptor (CAAR) containing the autoantigen desmoglein-3 (desmoglein 3; DSG3) that is fused to the co-stimulatory domain of 4-1BB (CD137) and the T-cell receptor signaling domain of CD3zeta (CD3z), with potential immunomodulatory activity. Upon administration, the autologous DSG3 chimeric autoantibody receptor T-cells (CAART) DSG3-CAART specifically recognize and induce selective toxicity in aberrant B-cells expressing DSG3 autoantibodies. This inhibits the production of DSG3 autoantibodies. DSG3 is a protein expressed in desmosomes that plays an important role in cell adhesion. DSG3 autoantibodies are produced and expressed by aberrant B-cells in the autoimmune disease mucosal-dominant pemphigus vulgaris.

**Synonyms:** - Autologous DSG3 CAART DSG3-CAART - Autologous DSG3 Chimeric Autoantibody Receptor T-cells DSG3-CAART - Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells DSG3-CAART - Autologous Desmoglein-3 CAAR-expressing T-cells DSG3-CAART - DSG3 CAART